5 Key Takeaways

• 1

  Lifitegrast 5% is an LFA-1 antagonist indicated for DED signs and symptoms that disrupts LFA-1–ICAM-1 interactions and inflammatory signaling.

• 2

  Across the OPUS trials, lifitegrast improved corneal staining in OPUS-1 and reduced eye dryness in OPUS-2 and OPUS-3, with symptom effects apparent by day 14.

• 3

  A pooled post hoc analysis of OPUS-2 and OPUS-3 found greater odds of clinically meaningful improvement in corneal staining and eye dryness with lifitegrast.

• 4

  In five randomized trials involving 2,464 patients, common adverse events included instillation-site irritation, reaction, or pain and dysgeusia; adverse-event discontinuations were relatively low.

• 5

  Real-world studies generally reported improvements in DED symptoms, signs, and quality of life, while the review noted treatment persistence challenges and disclosed industry support and author relati